Table 4 Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 2, 4, and 6

Patients who complete, N

14

10

4

11

1

10

152

36

109

7

 All durations

100 (78.5–100)

100 (72.2–100)

100 (51.0–100)

90.9 (62.3–98.4)

100 (20.7–100)

90.0 (59.6–98.2)

96.7 (92.5–98.6)

97.2 (85.8–99.5)

96.3 (90.9–98.6)

100 (64.6–100)

 12-wk treatment

100 (77.2–100)

100 (70.1–100)

100 (51.0–100)

87.5 (52.9–97.8)

100 (20.7–100)

85.7 (48.7–97.4)

97.1 (92.9–98.9)

97.0 (84.7–99.5)

97.0 (91.5–99.0)

100 (64.6–100)

 16-wk treatment

NA

NA

NA

NA

NA

NA

100 (34.2–100)

NA

100 (34.2–100)

NA

 24-wk treatment

100 (20.7–100)

100 (20.7–100)

NA

100 (43.9–100)

NA

100 (43.9–100)

90.0 (59.6–98.2)

100 (43.9–100)

85.7 (48.7–97.4)

NA

 No cirrhosis

100 (74.1–100)

100 (64.6–100)

100 (51.0–100)

100 (61.0–100)

100 (20.7–100)

100 (56.6–100)

96.8 (90.9–98.9)

100 (82.4–100)

95.8 (88.5–98.6)

100 (43.9–100)

 Cirrhosis

100 (43.9–100)

100 (43.9–100)

NA

80.0 (37.6–96.4)

NA

80.0 (37.6–96.4)

96.6 (88.5–99.1)

94.4 (74.2–99.0)

97.3 (86.2–99.5)

100 (51.0–100)

 Decompensated cirrhosis

100 (20.7–100)

100 (20.7–100)

NA

100 (20.7–100)

NA

100 (20.7–100)

100 (67.6–100)

100 (34.2–100)

100 (56.6–100)

100 (20.7–100)

 Treatment-naive

100 (75.8–100)

100 (67.6–100)

100 (51.0–100)

83.3 (43.6–97.0)

NA

83.3 (43.6–97.0)

99.1 (94.8–99.8)

100 (88.6–100)

98.6 (92.3–99.7)

100 (61.0–100)

 Treatment-experienced

100 (34.2–100)

100 (34.2–100)

NA

100 (56.6–100)

100 (20.7–100)

100 (51.0–100)

91.3 (79.7–96.6)

83.3 (43.6–97.0)

92.3 (79.7–97.3)

100 (20.7–100)